Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 7/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CLK1 | P49759 | 4/20 | 0.34 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
| ▸ | CLK2 | P49760 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20557570 | 1.00 | TYK2 (0.46) | TYK2PDE4DNR3C1MEN1KMT2A | |
| SCHEMBL16794695 | 0.93 | TYK2 (0.44) | TYK2PDE4DNR3C1MEN1KMT2A | |
| SCHEMBL16794714 | 0.93 | TYK2 (0.49) | TYK2PDE4DNR3C1MEN1KMT2A | |
| SCHEMBL16812479 | 0.90 | TYK2 (0.40) | TYK2PDE4DNR3C1MEN1KMT2A | |
| SCHEMBL16812493 | 0.87 | NR3C1 (0.39) | NR3C1MEN1KMT2ACLK1PDE1B | |
| SCHEMBL16812352 | 0.85 | PDE1B (0.38) | NR3C1MEN1KMT2APDE1BACLY | |
| SCHEMBL16812354 | 0.85 | CDK5 (0.39) | NR3C1MEN1KMT2ACLK1PDE1B | |
| SCHEMBL16812355 | 0.84 | ALDH1A1 (0.39) | TYK2NR3C1MEN1KMT2APDE1B | |
| SCHEMBL16812480 | 0.83 | JAK1 (0.38) | TYK2PDE4DNR3C1MEN1KMT2A | |
| SCHEMBL16794676 | 0.82 | PDE1B (0.40) | NR3C1MEN1KMT2APDE1BACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3377496-B1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2020-09-16 | — | — | EP | disclosed |
| EP-3377496-B1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2020-09-16 | — | — | EP | disclosed |
| US-10479793-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-11-19 | — | — | US | disclosed |
| US-20180325899-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2018-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479793-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | TYK2, IL2, JAK3 | TYK2 1/4885PDE4D 1794/4885NR3C1 1291/4885 |
| US-20180325899-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | TYK2, IL2, JAK3 | TYK2 1/4885PDE4D 1794/4885NR3C1 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.